日水製薬(株)の貸借残高情報
主市場 | 業種 | 証券コード/EDINET | 英名称 |
---|---|---|---|
東証PRM | 医薬品 | 4550/E00971 | Nissui Pharmaceutical Co., Ltd |
公表日 | 公表 | 貸付残高 | 前週比 | 新規貸付成約高 | 前週比 | 借入残高 | 前週比 | 新規借入成約高 | 前週比 |
---|---|---|---|---|---|---|---|---|---|
2017/12/01 | 日証協 | 63,300株 | -3.65% | 5,300株 | +278.57% | 147,938株 | +0.75% | 6,000株 | +1400% |
2017/11/24 | 日証協 | 65,700株 | -1.5% | 1,400株 | -22.22% | 146,838株 | -2.39% | 400株 | -84.62% |
2017/11/17 | 日証協 | 66,700株 | +1.52% | 1,800株 | +500% | 150,438株 | +0.4% | 2,600株 | +8.33% |
2017/11/10 | 日証協 | 65,700株 | +0.46% | 300株 | -93.62% | 149,838株 | +0.2% | 2,400株 | +33.33% |
2017/11/02 | 日証協 | 65,400株 | +0.31% | 4,700株 | -62.4% | 149,539株 | +1.01% | 1,800株 | +198.51% |
2017/10/27 | 日証協 | 65,200株 | +0.93% | 12,500株 | +303.23% | 148,039株 | -0.33% | 603株 | +50.75% |
2017/10/20 | 日証協 | 64,600株 | +0.62% | 3,100株 | +1450% | 148,536株 | -1.33% | 400株 | -69.23% |
2017/10/13 | 日証協 | 64,200株 | -0.31% | 200株 | -50% | 150,536株 | +0.2% | 1,300株 | -91.77% |
2017/10/06 | 日証協 | 64,400株 | -29% | 400株 | -99.29% | 150,236株 | +86.16% | 15,800株 | -90.25% |
2017/09/29 | 日証協 | 90,700株 | +118.55% | 56,100株 | +6133.33% | 80,702株 | -47.75% | 162,000株 | +9999.99% |
2017/09/22 | 日証協 | 41,500株 | +0.97% | 900株 | -95.57% | 154,439株 | -4.51% | 1,300株 | -96.08% |
2017/09/15 | 日証協 | 41,100株 | +51.66% | 20,300株 | +5.18% | 161,739株 | +23.62% | 33,200株 | +142.34% |
2017/09/08 | 日証協 | 27,100株 | +105.3% | 19,300株 | +865% | 130,839株 | +3.64% | 13,700株 | +1145.45% |
2017/09/01 | 日証協 | 13,200株 | -13.16% | 2,000株 | -39.39% | 126,239株 | -3.66% | 1,100株 | +22.22% |
2017/08/25 | 日証協 | 15,200株 | -22.05% | 3,300株 | -55.41% | 131,039株 | -3.03% | 900株 | -83.64% |
2017/08/18 | 日証協 | 19,500株 | +17.47% | 7,400株 | +2.78% | 135,139株 | +1.58% | 5,500株 | +243.75% |
2017/08/10 | 日証協 | 16,600株 | +25.76% | 7,200株 | +7100% | 133,039株 | -0.75% | 1,600株 | -44.83% |
2017/08/04 | 日証協 | 13,200株 | -7.69% | 100株 | -99.14% | 134,039株 | -0.45% | 2,900株 | +70.59% |
2017/07/28 | 日証協 | 14,300株 | -4.03% | 11,600株 | -14.71% | 134,639株 | -1.61% | 1,700株 | -22.73% |
※株式分割は考慮していませんのでご注意ください。